Gillmore et al. successfully edited the transthyretin (TTR) gene in the adult human liver for treating human hereditary transthyretin (hATTR) amyloidosis by intravenously injecting lipid nanoparticles encapsulating Cas9 mRNA and TTR gene targeting single guide RNA (sgRNA) (Batista and Flotte, 2021; Gillmore et al., 2021). This evidence concerns the gene TTR and amyloidosis.